MIB Agents OsteoBites and osTEAo

MIB Agents Osteosarcoma
  • 5.0 (5)
  • Medicine
  • Updated Monthly

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

  1. 5d ago

    Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade

    Osteosarcoma Webinar Series: Dr. Jing Huang is a Senior Investigator and Head of the Cancer and Stem Cell Epigenetics Group in the Laboratory of Cancer Biology and Genetics at the National Cancer Institute (NCI). He received his bachelor’s degree in Biochemistry from Peking University and his Ph.D. in Biochemistry and Biophysics from the University of Rochester, followed by postdoctoral training in cancer epigenetics at the Wistar Institute. Dr. Huang joined the NCI as a Principal Investigator in 2008 and earned tenure in 2016. His laboratory investigates transcriptional and epigenetic regulation in cancer and stem cells, with a major focus on the oncogenic driver RUNX2 in osteosarcoma. His ultimate goal is to develop novel therapeutic strategies and translate laboratory discoveries into clinical advances for osteosarcoma patients.

  2. Jul 16

    osTEAo: Live from FACTOR '26!

    Recorded live at FACTOR 2026, this episode of osTEAo features conversations with OsteoWarriors, OsteoSiblings, parents and family members, as well as the behind-the-scenes volunteers and staff who help make FACTOR possible. Guests share their experiences, favorite memories, and what this community means to them, offering a glimpse into the connection, support, and sense of belonging that define the annual conference. This in-person recording offers a look at the people and moments that make FACTOR and osTEAo so important.

  3. Jun 18

    osTEAo: Advocacy Doesn't End at Discharge

    In this episode of osTEAo, Sammy and Inaaya are joined by Elise, Sloane, and Camille for a conversation about self-advocacy and how it evolves after an osteosarcoma diagnosis. The group shares personal experiences navigating college, careers, travel, accessibility, and everyday life as survivors and individuals with disabilities. From campus accommodations to airport encounters, they discuss the challenges of speaking up for their needs, finding supportive communities, and learning how to navigate a world that isn't always built with accessibility in mind.

  4. Jun 5

    Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma

    Osteosarcoma Webinar Series: Barbara VanHare from the Rare Cancer Research Foundation will discuss the key role patients can play in accelerating Osteosarcoma breakthroughs through the donation of excess tissue and clinical data. She will walk through current barriers in rare cancer research, why each patient's story and tissue is important and cover the different ways to participate, all at no cost to the patient or their families.

  5. May 29

    A Guide to FACTOR 2026 Scientific Panels

    Matteo Trucco, MD, joins us on OsteoBites to break down the scientific panels featured at the 2026 FACTOR conference. From clinical trials to the latest advances in osteosarcoma research, Dr. Trucco will guide attendees through the key themes and conversations shaping FACTOR 2026. Whether you are attending FACTOR for the first time or returning for another year, this preview is a great way to feel more informed and connected ahead of the conference next month.

  6. May 22

    osTEAo - More Than Physical: The Mental Toll of Cancer

    In this episode of osTEAo, OsteoWarriors share honest and personal reflections on the mental health challenges that can come with diagnosis, treatment, surgery, and survivorship. They talk about the fear, isolation, and loss of normalcy that often come with cancer, especially as young people trying to navigate school, relationships, identity, and everyday life at the same time. From struggling to ask for help to finding comfort in community and people who truly understand, the discussion highlights the importance of support systems, vulnerability, and open conversations around mental health throughout the journey. This episode also welcomes osTEAo's new co-host, Inaaya!

  7. May 15

    A Phase 1/2, Study to Evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in Patients with Relapsed/Refractory Osteosarcoma

    David Shulman, MD, joins us on OsteoBites to discuss the newly opened phase 1/2 study to evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in patients with relapsed/refractory osteosarcoma. For many years, LRRC15 has been known to be an important target in osteosarcoma. A prior study showed a strong signal of activity of an LRRC15-targeted therapy in osteosarcoma; however, the development of the agent was not pursued. There is now a novel LRRC15-targeting radiopharmaceutical that has entered clinical trials for patients with osteosarcoma, and Dr. Shulman will provide an overview of this newly opened trial. Dr. David Shulman is a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute, where he also serves as an Assistant Professor of Pediatrics at Harvard Medical School. As the Director of the DFCI AYA Sarcoma Program, he focuses his clinical practice on the specialized care of adolescents and young adults (AYA) diagnosed with sarcomas. His research program, which has received support from the NIH and Harvard Catalyst, is dedicated to improving patient outcomes through the investigation of novel therapeutic approaches and the utility of circulating tumor DNA (ctDNA) as a clinical biomarker. He leads a national liquid biopsy study for patients with Ewing sarcoma and osteosarcoma, known as the LEOPARD study.

  8. May 8

    Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma

    Andrew Clugston, PhD, a postdoctoral fellow in the Sweet-Cordero Lab at UCSF joins us on OsteoBites to discuss his OutSmarting Osteosarcoma funded work, in partnership with the RISE Foundation, on defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma. The genomes of osteosarcoma (OS) cancer cells are among the most complex cancer genomes ever observed. Initially formed by hundreds to thousands of incorrectly repaired DNA breaks (structural variants; SVs), OS genomes contain DNA structures that are unique to that patient and tumor cell, combining genes and regulatory features from across the genome in ways that effectively re-wire that cell’s gene expression mechanisms. OS cells are also susceptible to further SVs over time and in response to treatment, potentially allowing OS tumors to evolve rapidly. But these complex and tumor-specific genomic structures may also harbor tumor-specific vulnerabilities. By mapping the many unique DNA structures among patient-derived OS tumor cells, Dr. Clugston has attempted to demonstrate that it is possible both to describe the essential structures within these cells and to search them for novel target genes vulnerable to existing drugs and treatment protocols. Using chromatin conformation capture sequencing (HiC) to observe the shape of the genome and optical genome mapping (OGM) to identify tumor-specific DNA structures, Dr. Clugston has produced tumor-specific maps for multiple patient-derived OS tumor cell lines and has begun development of a search process based on long-read mapping techniques that he hopes will inform future patient-specific treatment protocols. Andrew Clugston grew up in the small town of Lake Luzerne, New York. He received a BS in Biochemistry and an MS in Chemistry at the Rochester Institute of Technology, and he received his PhD in Integrative Systems Biology at the University of Pittsburgh. During his PhD he learned to use and develop bioinformatics tools and techniques to study the role of the genome in kidney as well as eye development, and in the process became fascinated with the importance of 3-dimensional organization in regulating cell behavior. Andrew has since joined the Sweet-Cordero laboratory in the Pediatric Oncology Division at the University of California San Francisco as a Postdoctoral Fellow. There, he applies his knowledge and skillset to study how disruptions in these organizational principles allow osteosarcoma cells to develop and proliferate, and how these changes reveal tumor-specific vulnerabilities that can be exploited for fast and effective treatment options that improve the lives of patients.

See All (221)

Ratings & Reviews

5
out of 5
5 Ratings

About

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

Information